SCHEMBL7652726

SCHEMBL7652726

CC(CNS(=O)(=O)C(C)C)C1CCN(C(=O)c2ccccc2)CC1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.53
ACHE P22303 1/20 0.50
GRIA2 P42262 2/20 0.47
GRIA4 P48058 2/20 0.47
EPHX1 P07099 1/20 0.47
BLM P54132 1/20 0.46
GRIA1 P42261 1/20 0.46
GRIA3 P42263 1/20 0.46
KMT2A Q03164 1/20 0.46
POLB P06746 2/20 0.45
L3MBTL3 Q96JM7 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
ADAM17 P78536 2/20 0.43
GPR119 Q8TDV5 1/20 0.43
LMNA P02545 1/20 0.43
TSHR P16473 1/20 0.43
ADAMTS7 Q9UKP4 3/20 0.43
ADAMTS5 Q9UNA0 3/20 0.43
ADAMTS4 O75173 1/20 0.43
MMP1 P03956 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8539143 0.79 ACHE (0.60) ALDH1A1ACHEEPHX1BLMKMT2A
SCHEMBL7468911 0.79 GRIA4 (0.53) ALDH1A1GRIA2GRIA4GRIA1GRIA3
SCHEMBL8545864 0.78 ACHE (0.59) ALDH1A1ACHEEPHX1BLMKMT2A
SCHEMBL14593670 0.76 ACHE (0.56) ALDH1A1ACHEEPHX1BLMKMT2A
SCHEMBL2603247 0.76 ACHE (0.68) ALDH1A1ACHEEPHX1BLMKMT2A
SCHEMBL5877287 0.75 GRIA4 (0.57) ALDH1A1GRIA2GRIA4POLBLMNA
SCHEMBL7320518 0.75 ACHE (0.66) ALDH1A1ACHEEPHX1BLMKMT2A
SCHEMBL7650121 0.74 HSD17B10 (0.50) ALDH1A1GRIA2GRIA4GRIA1GRIA3
SCHEMBL9785724 0.74 ACHE (0.64) ALDH1A1ACHEEPHX1BLMKMT2A
SCHEMBL7469275 0.73 GRIA2 (0.47) ALDH1A1GRIA2GRIA4GRIA1GRIA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6355655-B1 TREATING A COGNITIVE DISORDER, A NEURO-DEGENERATIVE DISORDER; AGE-RELATED DEMENTIA; AGE-INDUCED MEMORY IMPAIRMENT; A MOVEMENT DISORDER, ATTENTION DEFICIT DISORDER; ATTENTION DEFICIT HYPERACTIVITY DISORDER; PSYCHOSIS; COGNITIVE DEFICITS ELI LILLY AND COMPANY 2002-03-12 US disclosed
EP-1100498-A4 HETEROCYCLIC SULPHONAMIDE DERIVATIVES LILLY CO ELI (US) 2001-10-24 EP disclosed
EP-1100498-A1 HETEROCYCLIC SULPHONAMIDE DERIVATIVES Eli Lilly & Company (US) 2001-05-23 EP disclosed
WO-2000006159-A1 HETEROCYCLIC SULPHONAMIDE DERIVATIVES ELI LILLY AND COMPANY (US) 2000-02-10 WO disclosed